This supplement presents major achievements and insights gained from the introduction, scale-up, and optimization of self-testing. Full details here.
Expanding HIV Self-Testing Impact and Innovations from the STAR Initiative
BMC Infectious Diseases Supplement
Join us as we Commemorate HIV Vaccine Awareness Day
As we prepare to commemorate HIV Vaccine Awareness Day (HVAD) on May 18, the field continues to see some modest scientific breakthroughs, while still facing extraordinary challenges.
An HIV Vaccine: Looking into the Future with Nina Russell
On HIV Vaccine Awareness Day in 2024, the field is confronting extraordinary breakthroughs and extraordinary challenges.
It’s considered one of the most important and most difficult scientific enterprises in the history of modern medicine—the hunt for an HIV vaccine. It has led to vast knowledge of HIV and the immune system, and to breakthrough technology (think COVID vaccines and mRNA platforms). But developing an effective HIV vaccine is still out of reach. Meanwhile, HIV incidence remains intractably high in hard-hit regions around the world, even as the field is hoping to speed up access to longer-acting PrEP. It’s a complex landscape, alongside incredibly complex science in HIV vaccine R&D.
In this episode of PxPulse, Dr. Nina Russell, Director of TB & HIV Research and Development for the Bill and Melinda Gates foundation, talks about where she sees promise in the science, the goals for an HIV vaccine, and why it has an essential role to play, alongside the scale up of PrEP.
Listen
Resources
- Just What is Discovery Medicine? And what Does it Mean for HIV Vaccine Research, May 16 webinar
- HIV Vaccine and Antibody Efficacy Trials to Date, infographic
- From the Lab to the Jab, issue briefs
- Evolving Strategies for an HIV Vaccine: One researcher explains where the field is going and why? (21:23), PxPulse episode
- Research Fundamentals: An HIV Vaccine — What’s the challenge and what’s the science? (12:03), PxPulse episode
Cabotegravir Long-Acting Injectable for Prevention
Frequently Asked Questions
Afrocab has developed a FAQ (below) that covers the topics of PrEP and explains how CAB-LA works, is taken, and its side effects.
Diversity, Equity and Access to HIV Research
On May 2, 2024, AVAC staffer Jessica Salzwedel gave a presentation on diversity, equity and access in HIV research at the Ending the HIV Epidemic Conference at Weill Cornell Medicine. Check out the full presentation in PDF format.
“When we think about what engagement is important for research, it involves building systems of trust.” – Jessica Salzwedel
Biomedical HIV Prevention Summit and PrEP in Black America Summit
AVAC Highlights
1,000+ community advocates, researchers, policy experts, federal public health leadership, medical and service providers attended the NMAC annual Biomedical HIV Prevention Summit in Seattle. The discussion and debate on PrEP access, especially for racial and ethnic minorities and key populations, PrEP research, care, policy and community-based programs are ones to follow.
The Years Ahead in Biomedical HIV Prevention Research
This graphic shows the updated status of large-scale prevention trials through the end of 2024.
Media Science Cafes
AVAC Capability Statement
Since 2012, AVAC has worked to strengthen the capacity of journalists to report on HIV prevention research and global health and science topics. Through its flagship Media Science Café Program, AVAC partners with health media associations in Kenya, Malawi, Tanzania, Uganda, Zambia and Zimbabwe to connect journalists with subject matter experts—researchers, policymakers and advocates—and help build the relationships needed to foster accurate and informed reporting of HIV, COVID and emerging health and science issues.
Allocation of Non-Commercial CAB for PrEP Supply in Low- and Middle-Income Countries, 2023-2025
HIV Vaccine and Antibody Efficacy Trials to Date
This infographic provides a comprehensive overview of HIV vaccine and antibody efficacy trials. Over 20 years and 12 trials, only two positive signals have been observed.